Medical Pharmacology: Chapter: Chapter 11 — Lipid Disorders -- Module: Module 4 — Non-Statin Lipid-Lowering Therapy: Ezetimibe and PCSK9 Inhibitors

Chapter: Chapter 11 — Lipid Disorders — Module: Module 4 — Non-Statin Lipid-Lowering Therapy: Ezetimibe and PCSK9 Inhibitors
Tier: Tier 2 — Conceptual Understanding (13 questions)

1. Ezetimibe and statins are frequently combined in clinical practice. Which of the following best explains why this combination produces greater LDL-C reduction than either agent alone, and identifies the compensatory hepatic response that makes the combination pharmacologically rational?

A) Ezetimibe inhibits hepatic HMG-CoA reductase via an allosteric site distinct from the statin binding site, producing additive enzyme inhibition; the combination prevents the statin-induced upregulation of NPC1L1 that would otherwise partially offset statin efficacy
B) Statins reduce hepatic cholesterol synthesis, triggering upregulation of LDL receptors and increased hepatic cholesterol demand; ezetimibe simultaneously blocks intestinal cholesterol absorption, reducing the biliary and dietary cholesterol supply that would otherwise partially satisfy that demand — the two mechanisms attack cholesterol homeostasis from opposite ends, producing complementary and additive LDL-C lowering
C) Ezetimibe inhibits PCSK9 secretion from enterocytes, preventing LDL receptor degradation in the intestinal wall; statins inhibit hepatic cholesterol synthesis independently, and the combination prevents both hepatic and intestinal PCSK9-mediated receptor loss simultaneously
D) Statins upregulate intestinal NPC1L1 expression as a compensatory response to reduced hepatic cholesterol synthesis; ezetimibe blocks this upregulated NPC1L1, specifically countering the statin-induced increase in intestinal absorption that would otherwise blunt the LDL-C lowering effect
E) Ezetimibe activates ABCA1 on hepatocyte membranes, increasing reverse cholesterol transport and HDL-C formation; statins reduce LDL particle synthesis directly; the combination addresses both LDL overproduction and impaired reverse transport simultaneously

ANSWER: B

Rationale:

When statin-mediated HMG-CoA reductase inhibition reduces intracellular hepatocyte cholesterol, the cell responds by upregulating SREBP-2 (sterol regulatory element-binding protein 2), which drives increased LDL receptor expression and increased hepatic demand for exogenous cholesterol — including cholesterol delivered from the intestine via chylomicrons and from LDL particles in the circulation. This compensatory demand means the liver becomes more reliant on intestinal cholesterol absorption to meet its needs, partially blunting the LDL-C lowering achieved by the statin alone. Ezetimibe, by blocking NPC1L1-mediated intestinal cholesterol absorption, reduces the supply of cholesterol available to meet this statin-induced hepatic demand. The result is that the liver must upregulate LDL receptors further to clear LDL-C from plasma, amplifying the LDL-C lowering effect. This complementary attack — statin reducing synthesis and driving receptor upregulation, ezetimibe reducing intestinal supply — is the pharmacological rationale for combination therapy and explains the approximately 15–20% additional LDL-C reduction ezetimibe provides on top of statin therapy. Option A: Ezetimibe does not inhibit HMG-CoA reductase at any site. Its molecular target is exclusively NPC1L1 on the intestinal brush-border membrane. The premise of allosteric HMG-CoA reductase inhibition by ezetimibe is pharmacologically incorrect. Option C: Ezetimibe does not inhibit PCSK9 secretion. PCSK9 inhibition is the mechanism of evolocumab, alirocumab, and inclisiran. Ezetimibe has no activity at PCSK9 and does not affect LDL receptor degradation directly. Option D: Statins do not upregulate intestinal NPC1L1 expression as a compensatory response. The compensatory response to statin-induced intracellular cholesterol depletion is hepatic SREBP-2 activation with LDL receptor upregulation — not intestinal NPC1L1 upregulation. The described mechanism is not established pharmacology. Option E: Ezetimibe does not activate ABCA1 or increase reverse cholesterol transport. ABCA1 activation and HDL-C formation are associated with LXR agonists and niacin, not ezetimibe. Ezetimibe's mechanism is restricted to NPC1L1 inhibition at the intestinal brush border.

2. A 38-year-old man presents with LDL-C of 310 mg/dL despite being on high-intensity statin therapy. His father died of a myocardial infarction at age 42. Genetic testing reveals a PCSK9 gain-of-function (GOF) mutation. Which of the following best describes the molecular consequence of this mutation and explains why it produces a clinical phenotype resembling familial hypercholesterolemia?

A) The PCSK9 GOF mutation increases transcription of the LDLR gene by activating SREBP-2 constitutively, producing excessive LDL receptor protein that paradoxically sequesters LDL particles intracellularly rather than clearing them from plasma
B) The PCSK9 GOF mutation causes PCSK9 to inhibit HMG-CoA reductase directly, reducing intracellular hepatocyte cholesterol and triggering a massive compensatory increase in VLDL secretion that drives LDL-C accumulation in plasma
C) The PCSK9 GOF mutation prevents PCSK9 from binding the LDL receptor, leaving the receptor constitutively active on the hepatocyte surface but unable to internalize LDL particles due to conformational changes in the EGF-A domain
D) The PCSK9 GOF mutation enhances PCSK9 binding affinity for the LDL receptor, accelerating receptor degradation in lysosomes after endocytosis and reducing the number of LDL receptors available on the hepatocyte surface to clear LDL-C from plasma — producing a phenotype of elevated LDL-C and premature atherosclerotic cardiovascular disease indistinguishable from heterozygous familial hypercholesterolemia caused by LDLR mutations
E) The PCSK9 GOF mutation causes PCSK9 to dimerize abnormally, cross-linking adjacent LDL receptors on the hepatocyte surface and forming receptor aggregates that are internalized en masse and degraded, removing all surface LDL receptors simultaneously rather than through the normal single-receptor cycling mechanism

ANSWER: D

Rationale:

Under normal physiology, PCSK9 binds the EGF-A domain of the LDL receptor (LDLR) on the hepatocyte surface. When the LDLR-LDL-PCSK9 complex is internalized via endocytosis, the acidic endosomal environment normally causes the LDLR to release LDL and recycle to the cell surface. When PCSK9 is bound, the complex is instead routed to lysosomal degradation — PCSK9 acts as a chaperone for receptor destruction. A gain-of-function PCSK9 mutation increases the binding affinity of PCSK9 for the LDLR, meaning more receptors are routed to lysosomal degradation per endocytic cycle, resulting in fewer surface LDL receptors and reduced LDL-C clearance from plasma. The clinical consequence — markedly elevated LDL-C, tendon xanthomas, corneal arcus, and premature ASCVD — is indistinguishable from heterozygous familial hypercholesterolemia caused by loss-of-function LDLR mutations, because both conditions reduce the functional LDL receptor pool on hepatocyte surfaces. This mechanistic overlap makes PCSK9 inhibitors highly effective in GOF mutation carriers, since restoring normal receptor recycling directly counters the pathological gain of PCSK9 activity. Option A: PCSK9 does not regulate LDLR gene transcription. LDLR gene expression is controlled by SREBP-2 in response to intracellular cholesterol levels. PCSK9 acts post-translationally on the LDLR protein. The premise of constitutive SREBP-2 activation by PCSK9 GOF mutation is mechanistically incorrect. Option B: PCSK9 does not inhibit HMG-CoA reductase. These are entirely distinct proteins with different cellular locations and functions. PCSK9 is a secreted serine protease acting extracellularly on surface LDLR; HMG-CoA reductase is an intracellular endoplasmic reticulum enzyme regulated by SREBP-2 and AMPK (AMP-activated protein kinase). Option C: PCSK9 GOF mutations increase, not decrease, PCSK9 binding to the LDLR. A mutation that prevented PCSK9-LDLR binding would function as a loss-of-function mutation, resulting in more receptor recycling and lower LDL-C — the opposite of the clinical phenotype seen in this patient. Option E: PCSK9 does not dimerize to cross-link LDL receptors. The described aggregate-formation mechanism is not established PCSK9 biology. PCSK9 acts as a monomer binding individual LDLR molecules; the described cross-linking mechanism is fabricated and does not reflect any known PCSK9 gain-of-function pathophysiology.

3. The FOURIER trial established the cardiovascular outcomes benefit of evolocumab added to statin therapy. A cardiologist is counseling a 61-year-old man with established atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains at 88 mg/dL on high-intensity rosuvastatin plus ezetimibe. Which of the following correctly applies the FOURIER trial evidence to guide the decision to add evolocumab?

A) FOURIER enrolled 27,564 patients with established ASCVD on optimized statin therapy and demonstrated that evolocumab reduced the primary composite cardiovascular endpoint by a relative 15% and LDL-C to a median of 30 mg/dL, with no increase in adverse events including new-onset diabetes or neurocognitive effects at achieved LDL-C levels below 20 mg/dL — supporting addition of evolocumab in this patient who remains above guideline LDL-C targets despite dual oral therapy
B) FOURIER demonstrated that evolocumab benefit was limited to patients with baseline LDL-C above 100 mg/dL; patients already achieving LDL-C below 90 mg/dL on statin therapy showed no statistically significant reduction in cardiovascular events, making evolocumab addition pharmacologically irrational in this patient whose LDL-C is already 88 mg/dL
C) FOURIER enrolled only statin-naive patients and demonstrated that evolocumab monotherapy reduced LDL-C by 60% from untreated baseline; the trial does not apply to patients already on combination statin plus ezetimibe therapy, as the background lipid-lowering regimen was not studied in FOURIER
D) FOURIER demonstrated cardiovascular benefit only for the secondary endpoint of myocardial infarction reduction, with no significant effect on the primary composite endpoint or cardiovascular mortality; the trial supports evolocumab use only for MI prevention in patients with prior MI, not for broad ASCVD risk reduction
E) FOURIER demonstrated that evolocumab produced cardiovascular benefit exclusively through LDL-C lowering to below 50 mg/dL; patients whose LDL-C does not fall below 50 mg/dL on evolocumab therapy show no event reduction, and treatment should be discontinued if the 50 mg/dL threshold is not achieved within 12 weeks

ANSWER: A

Rationale:

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease — defined as prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease — who were on optimized statin therapy with LDL-C of 70 mg/dL or above at baseline. Evolocumab reduced LDL-C by approximately 59% from a median baseline of 92 mg/dL, achieving a median on-treatment LDL-C of 30 mg/dL. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by a relative 15% (9.8% vs. 11.3%, p<0.001). The key secondary endpoint — cardiovascular death, MI, or stroke — was reduced by 20%. Importantly, no increase in adverse effects including new-onset diabetes, neurocognitive effects, or hemorrhagic stroke was observed even at LDL-C levels below 20 mg/dL, reinforcing the safety of aggressive LDL-C lowering. For the patient in this question, who has established ASCVD and LDL-C of 88 mg/dL above the guideline target of less than 70 mg/dL (or less than 55 mg/dL for very high risk) on maximal oral therapy, FOURIER directly supports the addition of evolocumab. Option B: FOURIER did not show that benefit was limited to patients with baseline LDL-C above 100 mg/dL. The trial enrolled patients with LDL-C of 70 mg/dL or above, and benefit was consistent across the enrolled LDL-C range. The "lower is better" principle applies continuously — there is no threshold below which further LDL-C reduction loses benefit in this population. Option C: FOURIER enrolled patients on optimized background statin therapy — not statin-naive patients. Approximately 69% of FOURIER enrollees were on high-intensity statins. The trial directly studied evolocumab added to statin therapy, which is precisely the scenario in this question. Option D: FOURIER demonstrated statistically significant reduction in the primary composite endpoint (p<0.001), not only in secondary endpoints. The trial is cited as evidence of broad ASCVD risk reduction, not MI-only prevention. Cardiovascular mortality alone was not significantly reduced in FOURIER, but the composite primary endpoint was — a distinction that does not support the characterization in this option. Option E: FOURIER does not specify a 50 mg/dL threshold below which benefit is conditional, nor does it support discontinuation based on failure to achieve a specific on-treatment LDL-C value within 12 weeks. The trial demonstrates benefit across a range of achieved LDL-C values, and treatment decisions are based on cardiovascular risk and tolerability, not a binary threshold response criterion.

4. A 67-year-old woman with established ASCVD and an LDL-C of 134 mg/dL has documented statin intolerance — she has developed myalgia confirmed by symptom recurrence on rechallenge with three different statins at low doses. Her creatine kinase (CK) levels are normal. Which of the following best describes the appropriate role of ezetimibe in her management and the evidence base supporting this approach?

A) Ezetimibe is contraindicated in statin-intolerant patients because its mechanism of blocking intestinal cholesterol absorption triggers a reflex increase in hepatic cholesterol synthesis that cannot be suppressed without concurrent statin therapy; without a statin, ezetimibe-induced upregulation of HMG-CoA reductase fully offsets its LDL-C lowering effect
B) Ezetimibe monotherapy is not appropriate for this patient because the IMPROVE-IT trial demonstrated ezetimibe benefit only as add-on to statin therapy; there is no evidence that ezetimibe monotherapy reduces cardiovascular events, and guidelines do not endorse its use outside of combination therapy
C) Ezetimibe monotherapy is an appropriate first-line alternative in truly statin-intolerant patients with established ASCVD; while ezetimibe alone produces a more modest LDL-C reduction of approximately 18–20% compared with high-intensity statins, it is well tolerated, has no skeletal muscle toxicity, and can be combined with a PCSK9 inhibitor if LDL-C targets are not achieved on ezetimibe alone
D) Ezetimibe should not be used in statin-intolerant patients because its hepatic glucuronidation pathway is competitively inhibited by the same CYP450 enzymes responsible for statin metabolism; co-administration would increase plasma statin concentrations and worsen myotoxicity even at low statin doses
E) Ezetimibe monotherapy produces equivalent LDL-C lowering to high-intensity statin therapy in statin-intolerant patients because NPC1L1 blockade at the intestinal brush border removes the primary source of hepatic cholesterol, fully compensating for the absence of HMG-CoA reductase inhibition

ANSWER: C

Rationale:

True statin intolerance — defined by reproducible myalgia or myopathy on rechallenge with multiple statins, in the absence of CK elevation sufficient to indicate myositis or rhabdomyolysis — affects a clinically significant minority of patients who require alternative LDL-C lowering strategies. Ezetimibe monotherapy is an established and guideline-supported option in this setting. It produces approximately 18–20% LDL-C reduction from baseline as monotherapy, which is substantially less than high-intensity statin therapy (approximately 50–55% reduction) but clinically meaningful for patients who cannot tolerate any statin dose. Ezetimibe has no skeletal muscle toxicity — it does not affect mitochondrial function, coenzyme Q10 levels, or muscle fiber integrity — which is pharmacologically expected given its exclusive intestinal mechanism. For patients whose LDL-C remains above target on ezetimibe monotherapy, the addition of a PCSK9 inhibitor (evolocumab or alirocumab) provides a further 50–60% reduction and does not involve any skeletal muscle mechanism, making triple-therapy avoidance of statins a viable strategy in truly intolerant patients. ACC/AHA guidelines support ezetimibe as a non-statin LDL-C lowering option in patients with statin intolerance and high cardiovascular risk. Option A: Ezetimibe is not contraindicated in statin-intolerant patients — this is the opposite of current evidence and guideline recommendations. While ezetimibe monotherapy does trigger a compensatory increase in hepatic cholesterol synthesis (via SREBP-2 activation), this is a partial offset, not a complete negation. Ezetimibe monotherapy consistently reduces LDL-C by approximately 18–20% even without concurrent statin therapy. Option B: While it is correct that IMPROVE-IT studied ezetimibe as add-on to statin therapy and did not directly study cardiovascular event reduction with ezetimibe monotherapy, the absence of a dedicated outcomes trial for ezetimibe monotherapy does not constitute a contraindication. Guidelines endorse ezetimibe use in statin-intolerant patients based on its LDL-C lowering efficacy and favorable safety profile, applying the established relationship between LDL-C reduction and cardiovascular risk reduction. Option D: Ezetimibe is not metabolized by CYP450 enzymes. Its primary metabolic pathway is glucuronidation via UGT (UDP-glucuronosyltransferase) enzymes, which are entirely distinct from the CYP3A4 and CYP2C9 pathways responsible for statin metabolism. The premise of competitive CYP450 inhibition between ezetimibe and statins is pharmacokinetically incorrect, and ezetimibe has an extremely low drug-drug interaction profile. Option E: Ezetimibe monotherapy does not produce equivalent LDL-C lowering to high-intensity statin therapy. Blocking intestinal cholesterol absorption with ezetimibe triggers a compensatory increase in hepatic cholesterol synthesis that substantially offsets the reduction in cholesterol delivery to the liver. High-intensity statins achieve approximately 50–55% LDL-C reduction; ezetimibe monotherapy achieves approximately 18–20%. These are not equivalent.

5. Inclisiran is a newer PCSK9-targeting agent approved for LDL-C lowering. Which of the following correctly distinguishes inclisiran's mechanism of action from that of evolocumab and alirocumab, and identifies the pharmacokinetic property that enables its unique dosing schedule?

A) Inclisiran is a small-molecule oral PCSK9 inhibitor that competitively blocks the catalytic domain of PCSK9 within hepatocyte endosomes, preventing PCSK9 from binding the LDL receptor intracellularly; its oral bioavailability and hepatic first-pass concentration effect enable once-daily dosing without injection
B) Inclisiran is a fully human monoclonal antibody targeting a different epitope on PCSK9 than evolocumab and alirocumab — specifically the prodomain cleavage site rather than the EGF-A binding domain — resulting in irreversible PCSK9 inactivation and a longer duration of action requiring only quarterly dosing
C) Inclisiran is a PCSK9 receptor decoy — a recombinant soluble LDL receptor fragment that binds circulating PCSK9 with high affinity, sequestering it before it can reach the hepatocyte surface; its large molecular size results in slow renal clearance, enabling twice-yearly subcutaneous dosing
D) Inclisiran is a PCSK9 vaccine that stimulates endogenous antibody production against PCSK9 protein; the immune response generates polyclonal anti-PCSK9 antibodies that persist for 6 months, requiring booster doses twice yearly to maintain therapeutic PCSK9 neutralization
E) Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA within hepatocytes, preventing PCSK9 protein synthesis at the translational level; its conjugation to GalNAc (N-acetylgalactosamine) enables selective hepatocyte uptake via ASGR1 receptors, and its intracellular stability in the RNA-induced silencing complex (RISC) enables twice-yearly subcutaneous dosing after the initial loading doses

ANSWER: E

Rationale:

Inclisiran is a synthetic double-stranded small interfering RNA (siRNA) that operates through RNA interference (RNAi) — a fundamentally different mechanism from the monoclonal antibody approach of evolocumab and alirocumab. Evolocumab and alirocumab are fully human monoclonal antibodies that bind and neutralize circulating PCSK9 protein extracellularly, preventing PCSK9 from reaching the LDL receptor on the hepatocyte surface. Inclisiran, by contrast, is taken up by hepatocytes via its GalNAc (N-acetylgalactosamine) conjugate, which binds ASGR1 (asialoglycoprotein receptor 1) expressed selectively on hepatocytes, enabling precise hepatic targeting. Once inside the hepatocyte, inclisiran is incorporated into the RNA-induced silencing complex (RISC), which uses the siRNA sequence to recognize and cleave PCSK9 mRNA before it can be translated into PCSK9 protein. The result is a reduction in PCSK9 protein synthesis of approximately 50%, with corresponding LDL-C reduction of approximately 50% from baseline. The key pharmacokinetic advantage of inclisiran is its stability within the RISC complex — the drug is not consumed by the cleavage reaction and the loaded RISC can cleave multiple PCSK9 mRNA transcripts over months, enabling dosing at day 1, day 90, and then every 6 months thereafter. This twice-yearly maintenance schedule is a substantial practical advantage over the every-2-week or monthly injections required for evolocumab and alirocumab. Option A: Inclisiran is not an oral agent and is not a small-molecule competitive inhibitor. It is a subcutaneously administered siRNA. Small-molecule oral PCSK9 inhibitors are in development but are not approved agents; inclisiran's mechanism is gene silencing at the mRNA level, not enzyme competitive inhibition. Option B: Inclisiran is not a monoclonal antibody. Characterizing it as targeting a different epitope than evolocumab or alirocumab confuses the mechanism category entirely. Inclisiran prevents PCSK9 protein from being synthesized; evolocumab and alirocumab neutralize PCSK9 protein after it has been secreted. These are mechanistically distinct approaches. Option C: Inclisiran is not a receptor decoy or recombinant soluble LDL receptor fragment. The concept of a soluble LDLR decoy binding circulating PCSK9 is biologically plausible but does not describe an approved agent. Inclisiran's prolonged action results from intracellular RISC stability, not from slow renal clearance of a large protein. Option D: Inclisiran is not a vaccine and does not stimulate endogenous antibody production. It is a synthetic siRNA that directly silences PCSK9 gene expression in hepatocytes. PCSK9 vaccine approaches are in preclinical and early clinical development but are not approved agents and are categorically different from siRNA gene silencing.

6. The ODYSSEY OUTCOMES trial examined alirocumab in a high-risk post-ACS population. A 55-year-old woman is hospitalized for an acute myocardial infarction. She is already on high-intensity atorvastatin. Her in-hospital LDL-C is 98 mg/dL. Which of the following correctly applies the ODYSSEY OUTCOMES evidence to her post-discharge management?

A) ODYSSEY OUTCOMES demonstrated that alirocumab benefit was restricted to patients with baseline LDL-C above 130 mg/dL; patients with in-hospital LDL-C below 100 mg/dL showed no statistically significant cardiovascular event reduction, making alirocumab addition inappropriate for this patient
B) ODYSSEY OUTCOMES enrolled 18,924 patients with recent ACS on maximized statin therapy and demonstrated that alirocumab reduced the primary composite endpoint of major adverse cardiovascular events by a relative 15%, reduced LDL-C to a median of 38 mg/dL, and was associated with a significant reduction in all-cause mortality in a pre-specified analysis — supporting alirocumab addition in this high-risk patient who remains above LDL-C target post-ACS
C) ODYSSEY OUTCOMES demonstrated that alirocumab benefit was limited to patients who had not previously received statin therapy; patients already on high-intensity statins at the time of the index ACS showed no incremental benefit from alirocumab addition, because PCSK9 inhibition cannot further reduce LDL-C below the nadir achieved by maximal statin doses
D) ODYSSEY OUTCOMES examined alirocumab in patients with stable coronary artery disease and chronic LDL-C elevation, not in acute coronary syndrome patients; applying its findings to post-ACS management requires caution because the post-ACS inflammatory milieu alters PCSK9 expression and LDL receptor biology in ways not captured by the stable CAD trial design
E) ODYSSEY OUTCOMES demonstrated that alirocumab reduced LDL-C effectively but produced no statistically significant reduction in the primary cardiovascular composite endpoint; the trial is cited only for its LDL-C lowering efficacy data and safety profile, not for cardiovascular event reduction evidence

ANSWER: B

Rationale:

The ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced an acute coronary syndrome (ACS) within the preceding 1 to 12 months and who were on optimized statin therapy (high-intensity or maximum tolerated dose) with LDL-C of 70 mg/dL or above, non-HDL cholesterol of 100 mg/dL or above, or apolipoprotein B of 80 mg/dL or above at randomization. Alirocumab 75 mg every 2 weeks (with dose adjustment to 150 mg if LDL-C remained above 50 mg/dL) was compared to placebo. The primary composite endpoint — coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization — was reduced by a relative 15% (9.5% vs. 11.1%, p<0.001). LDL-C was reduced to a median of 38 mg/dL in the alirocumab arm. A pre-specified sensitivity analysis demonstrated a significant reduction in all-cause mortality (3.5% vs. 4.1%, HR 0.85, p=0.026), which was not observed in FOURIER and represents a clinically important finding. For the patient in this question — post-ACS with LDL-C of 98 mg/dL above guideline target on high-intensity statin — ODYSSEY OUTCOMES directly supports alirocumab addition at discharge or early in the post-ACS period. Option A: ODYSSEY OUTCOMES did not restrict benefit to patients with LDL-C above 130 mg/dL. The enrollment threshold was LDL-C of 70 mg/dL or above (or non-HDL or apoB thresholds), and the trial demonstrated consistent benefit across LDL-C subgroups. The "lower is better" principle applies throughout the enrolled range. Option C: ODYSSEY OUTCOMES enrolled patients already on maximized statin therapy — the entire enrolled population was on high-intensity or maximum-tolerated statins. The trial directly and specifically demonstrated incremental benefit of alirocumab added to statin therapy, which is the exact scenario presented in this question. The premise that statin-pretreated patients show no benefit is the opposite of the trial findings. Option D: ODYSSEY OUTCOMES enrolled post-ACS patients specifically — not stable CAD patients. The trial was designed for the post-ACS high-risk population and its findings are most directly applicable to exactly the scenario in this question. FOURIER enrolled stable ASCVD patients; ODYSSEY OUTCOMES enrolled post-ACS patients. Option E: ODYSSEY OUTCOMES demonstrated statistically significant reduction in the primary composite cardiovascular endpoint (p<0.001) and a significant reduction in all-cause mortality in a pre-specified analysis. Characterizing the trial as showing only LDL-C lowering without cardiovascular event reduction is factually incorrect and contradicts the trial's primary finding.

7. A patient on rosuvastatin 40 mg has an LDL-C of 95 mg/dL. His physician adds evolocumab 140 mg every 2 weeks. Which of the following best explains why evolocumab produces a substantially greater absolute LDL-C reduction when added to statin therapy than when used as monotherapy in a statin-naive patient with the same baseline LDL-C?

A) Statin therapy increases hepatic PCSK9 secretion as a compensatory response to LDL receptor upregulation; evolocumab added to a statin therefore neutralizes a larger circulating PCSK9 burden than it would in a statin-naive patient, amplifying the number of LDL receptors it protects from degradation and producing greater absolute LDL-C lowering
B) Evolocumab upregulates NPC1L1 expression on intestinal enterocytes as an off-target effect of PCSK9 inhibition; when added to a statin, this upregulation is blocked by the statin's secondary effect on intestinal gene transcription, eliminating a mechanism that would otherwise partially offset evolocumab's LDL-C lowering in statin-naive patients
C) Statin therapy reduces plasma albumin binding of evolocumab by competing for shared serum protein binding sites, increasing the free fraction of evolocumab available to bind circulating PCSK9 and proportionally increasing the LDL receptor-protective effect per milligram of evolocumab administered
D) Statin therapy upregulates hepatic LDL receptor expression via SREBP-2 activation; when evolocumab simultaneously prevents PCSK9-mediated degradation of these statin-induced receptors, the net surface LDL receptor density is substantially higher than either agent produces alone — creating a multiplicative rather than simply additive effect on LDL-C clearance from plasma
E) Evolocumab has greater bioavailability when co-administered with statins because statins inhibit CYP3A4, reducing evolocumab's first-pass hepatic metabolism and increasing peak plasma concentrations of the antibody; the pharmacokinetic interaction directly explains the superior LDL-C lowering observed with combination therapy

ANSWER: D

Rationale:

The enhanced LDL-C lowering of evolocumab added to statin therapy compared with either agent alone reflects a pharmacodynamic synergy operating at the level of hepatocyte LDL receptor surface density. Statins inhibit HMG-CoA reductase, reducing intracellular hepatocyte cholesterol and activating SREBP-2, which transcriptionally upregulates LDL receptor expression — increasing the number of LDL receptor molecules synthesized and inserted into the hepatocyte surface. However, this increased receptor pool is partially offset by PCSK9-mediated receptor degradation — PCSK9 is itself transcriptionally upregulated by SREBP-2 alongside LDL receptors, meaning statin therapy simultaneously increases both LDL receptor production and LDL receptor destruction via PCSK9. Evolocumab, by neutralizing circulating PCSK9, prevents the degradation of the statin-induced receptor pool, allowing the full complement of SREBP-2-upregulated receptors to remain on the hepatocyte surface and recycle efficiently. The result is a surface LDL receptor density substantially greater than either agent produces alone — statins drive receptor synthesis, evolocumab prevents receptor destruction — which translates into markedly enhanced LDL-C clearance from plasma. This mechanistic synergy is why PCSK9 inhibitors added to high-intensity statins routinely reduce LDL-C by 60% or more from the on-statin baseline. Option A: The statement that statin therapy increases hepatic PCSK9 secretion as a compensatory response is partially correct — SREBP-2 does upregulate PCSK9 transcription alongside LDL receptors. However, the explanation that this produces a larger PCSK9 burden for evolocumab to neutralize is not the primary mechanistic explanation for the enhanced LDL-C lowering. The key mechanism is that evolocumab protects the statin-induced receptor pool from degradation, not simply that there is more PCSK9 to neutralize. Option B: Evolocumab does not upregulate intestinal NPC1L1 expression. PCSK9 inhibition has no established effect on NPC1L1 expression or intestinal cholesterol absorption. The described off-target effect is not part of evolocumab's pharmacology. Option C: Evolocumab is a monoclonal antibody — large biologics are not metabolized by CYP450 enzymes and do not undergo first-pass hepatic metabolism. Statins do not affect monoclonal antibody pharmacokinetics. The described albumin-binding competition is not established pharmacology for any approved monoclonal antibody. Option E: Evolocumab is a monoclonal antibody that is administered subcutaneously and is eliminated via proteolytic degradation, not by CYP3A4. Statins do not affect evolocumab bioavailability or plasma concentrations. There is no pharmacokinetic interaction between statins and PCSK9 inhibitor monoclonal antibodies.

8. Sitosterolemia (phytosterolemia) is a rare autosomal recessive disorder caused by loss-of-function mutations in ABCG5 or ABCG8, resulting in massive accumulation of plant sterols (sitosterol, campesterol) in plasma and tissues. A 24-year-old man with sitosterolemia presents with xanthomas and a plasma sitosterol level of 28 mg/dL (normal less than 1 mg/dL). Which of the following correctly explains why ezetimibe is effective in reducing plant sterol accumulation in this disorder, and why statins alone are insufficient?

A) Ezetimibe blocks NPC1L1 on the intestinal brush-border membrane, which mediates absorption of both cholesterol and non-cholesterol sterols including plant sterols; by reducing intestinal uptake of sitosterol and campesterol, ezetimibe decreases the substrate load entering the portal circulation, directly addressing the absorptive excess that underlies sitosterolemia — statins alone are insufficient because they reduce cholesterol synthesis but do not address the defective sterol secretion back into the intestinal lumen caused by ABCG5/G8 loss
B) Ezetimibe directly activates the residual ABCG5/G8 heterodimer by allosteric binding to the Walker A motif of the ABCG8 subunit, partially restoring the sterol efflux transporter function lost in sitosterolemia; statins are insufficient because they upregulate SREBP-2, which transcriptionally suppresses ABCG5/G8 expression and worsens the underlying transport defect
C) Ezetimibe inhibits hepatic PCSK9 secretion, increasing LDL receptor density on hepatocyte surfaces; increased hepatic LDL receptor activity preferentially clears plant sterol-enriched LDL particles from the circulation because plant sterols have higher LDL receptor binding affinity than cholesterol — statins do not share this selectivity for plant sterol-enriched particles
D) Ezetimibe inhibits microsomal triglyceride transfer protein (MTP) in enterocytes, blocking assembly of plant sterol-containing chylomicrons; without chylomicron assembly, absorbed plant sterols accumulate in enterocytes and are eventually shed into the intestinal lumen with enterocyte turnover rather than entering the portal circulation — statins reduce chylomicron remnant clearance and worsen this pathway
E) Ezetimibe reduces hepatic cholesterol synthesis by a mechanism independent of HMG-CoA reductase — specifically by inhibiting lanosterol 14-alpha-demethylase in the late cholesterol synthesis pathway — which diverts the enzymatic machinery away from plant sterol processing; statins target only the early committed step and cannot reduce plant sterol synthesis because plant sterols are entirely of dietary origin

ANSWER: A

Rationale:

In sitosterolemia, loss-of-function mutations in ABCG5 or ABCG8 — which form a heterodimeric ABC transporter on both intestinal enterocyte apical membranes and hepatocyte canalicular membranes — eliminate the normal mechanism by which plant sterols are secreted back into the intestinal lumen (preventing absorption) and excreted into bile (promoting elimination). The result is massive intestinal hyperabsorption of plant sterols (normally absorbed at less than 5% efficiency, rising to 15–60% in sitosterolemia) and impaired biliary elimination. NPC1L1, the transporter targeted by ezetimibe, mediates absorption of sterols broadly — including both cholesterol and non-cholesterol sterols such as sitosterol and campesterol — from the intestinal lumen into enterocytes. By blocking NPC1L1, ezetimibe reduces the intestinal uptake of plant sterols, decreasing the load entering the portal circulation and substantially lowering plasma plant sterol levels. This is a rational therapeutic intervention in sitosterolemia, supported by clinical evidence showing meaningful reductions in plasma sitosterol and campesterol with ezetimibe therapy. Statins are insufficient as monotherapy because they address hepatic cholesterol synthesis — not the intestinal absorptive excess and defective sterol secretion that are the primary pathological mechanisms in sitosterolemia. A low plant sterol diet combined with ezetimibe is the cornerstone of management. Option B: Ezetimibe does not allosterically activate ABCG5/G8. Ezetimibe has no known interaction with ABC transporters. Its sole established molecular target is NPC1L1. The described Walker A motif binding is fabricated and does not reflect ezetimibe's pharmacology. Option C: Ezetimibe does not inhibit hepatic PCSK9 secretion. This is the mechanism of evolocumab, alirocumab, and inclisiran. Furthermore, plant sterols do not have preferential LDL receptor binding affinity relative to cholesterol — this mechanistic premise is not established in sterol biology. Option D: Ezetimibe does not inhibit microsomal triglyceride transfer protein (MTP). MTP inhibition is the mechanism of lomitapide. Ezetimibe's mechanism is restricted to NPC1L1 blockade at the intestinal brush-border membrane, not chylomicron assembly inhibition. Option E: Ezetimibe does not inhibit lanosterol 14-alpha-demethylase or any other step in the cholesterol synthesis pathway. It has no mechanism in cholesterol synthesis and no activity against any enzyme in the sterol biosynthesis pathway. Its mechanism is entirely at the level of intestinal sterol absorption via NPC1L1.

9. Population genetic studies identified individuals with heterozygous loss-of-function (LOF) mutations in PCSK9 who have lifelong LDL-C levels approximately 28% below population means. Long-term follow-up of these individuals provided pivotal evidence that shaped the development of PCSK9 inhibitors. Which of the following correctly describes what these LOF mutation carriers demonstrated, and why this evidence was considered proof-of-concept for PCSK9 inhibition as a therapeutic strategy?

A) PCSK9 LOF mutation carriers demonstrated that lifelong low LDL-C was associated with a 28% reduction in LDL-C but paradoxically no reduction in cardiovascular events, because the duration of LDL-C lowering — not the magnitude — is the primary determinant of atherosclerotic risk reduction; this finding prompted researchers to develop PCSK9 inhibitors that could be initiated early in life for maximum duration
B) PCSK9 LOF mutation carriers demonstrated that very low LDL-C levels below 30 mg/dL were associated with significant increases in hemorrhagic stroke, cognitive impairment, and adrenal insufficiency — safety signals that were subsequently addressed in the drug development program by designing PCSK9 inhibitors that produce less complete PCSK9 neutralization than the LOF genotype
C) PCSK9 LOF mutation carriers demonstrated a 88% reduction in the risk of coronary heart disease relative to the general population despite only a 28% reduction in LDL-C — a disproportionate cardiovascular benefit attributed to lifelong exposure from birth, which validated PCSK9 as a genuine therapeutic target and supported the hypothesis that earlier and more sustained LDL-C lowering produces greater cardiovascular benefit than later intervention at equivalent LDL-C levels
D) PCSK9 LOF mutation carriers demonstrated equivalent cardiovascular event rates to the general population when LDL-C differences were statistically adjusted, confirming that PCSK9 affects cardiovascular risk through LDL-C-independent pathways including vascular inflammation and endothelial PCSK9 receptors — findings that prompted the development of PCSK9 inhibitors as anti-inflammatory agents rather than purely lipid-lowering drugs
E) PCSK9 LOF mutation carriers demonstrated complete absence of atherosclerotic plaque formation by coronary CT angiography despite normal blood pressure and inflammatory markers, establishing that PCSK9 inhibition alone — without statin co-administration — is sufficient to prevent all atherosclerosis in genetically susceptible individuals, which is why early PCSK9 inhibitor trials enrolled statin-naive patients exclusively

ANSWER: C

Rationale:

The pivotal epidemiological evidence came from two landmark analyses. Cohen et al. (2006) in the New England Journal of Medicine analyzed large prospective cohort data from the ARIC (Atherosclerosis Risk in Communities) study and identified Black Americans carrying sequence variants that reduced PCSK9 function. Those with a 28% lower LDL-C due to LOF PCSK9 variants had an 88% lower risk of coronary heart disease over 15 years compared with those without the variants. This disproportionate risk reduction — 88% reduction in CHD risk from a 28% reduction in LDL-C — was attributed to the lifelong nature of the LDL-C lowering beginning from birth, consistent with the Mendelian randomization principle that genetic variants conferring lifelong exposure to a lower risk factor produce cardiovascular benefits far larger than those observed in drug trials of equivalent magnitude started in middle age. This finding provided proof-of-concept that PCSK9 was a validated therapeutic target: reducing PCSK9 function produced profound cardiovascular protection, was safe over decades of observation, and supported the development of pharmacological PCSK9 inhibition. The LOF carrier data also confirmed the "lower is better and earlier is better" hypothesis for LDL-C lowering that underpins current guideline recommendations for aggressive lipid management. Option A: PCSK9 LOF mutation carriers did not show absence of cardiovascular benefit. The ARIC cohort data demonstrated an 88% reduction in coronary heart disease risk — one of the most striking genetic cardiovascular risk reduction findings in modern cardiology. The premise that there was no event reduction is factually incorrect. Option B: PCSK9 LOF mutation carriers did not demonstrate increases in hemorrhagic stroke, cognitive impairment, or adrenal insufficiency. These safety concerns were raised theoretically before the outcomes trials but were not borne out in the LOF mutation data, in FOURIER, or in ODYSSEY OUTCOMES. The LOF data were reassuring for safety, not alarming. Option D: PCSK9 LOF mutation carriers demonstrated cardiovascular benefit that was directly proportional to their LDL-C reduction when analyzed via Mendelian randomization, supporting LDL-C as the operative mediator. The evidence does not establish LDL-C-independent vascular mechanisms as the primary driver, and PCSK9 inhibitors were developed specifically as LDL-C lowering agents. Option E: PCSK9 LOF mutation carriers were not studied exclusively by coronary CT angiography for plaque absence, and the data do not establish complete absence of atherosclerosis. Furthermore, FOURIER and ODYSSEY OUTCOMES enrolled patients predominantly on statin therapy — not statin-naive patients — consistent with the established principle that PCSK9 inhibitors work synergistically with statins.

10. A patient on ezetimibe 10 mg daily for LDL-C lowering is started on cyclosporine for renal transplant immunosuppression. His pharmacist flags a potential drug interaction. Which of the following correctly identifies the pharmacokinetic basis of this interaction and the appropriate clinical response?

A) Cyclosporine is a potent CYP3A4 inhibitor; since ezetimibe is primarily metabolized by CYP3A4 to its active glucuronide, cyclosporine substantially increases plasma ezetimibe concentrations by reducing first-pass metabolism — the combination requires dose reduction of ezetimibe to 5 mg daily and monitoring of liver enzymes
B) Cyclosporine induces intestinal P-glycoprotein (P-gp) expression, increasing ezetimibe efflux from enterocytes back into the intestinal lumen and reducing the amount of ezetimibe reaching its NPC1L1 target; the net effect is a clinically significant reduction in ezetimibe efficacy requiring dose escalation to 20 mg daily to maintain LDL-C lowering
C) Cyclosporine competitively inhibits renal tubular secretion of ezetimibe-glucuronide, the primary renal elimination pathway for ezetimibe's active metabolite; reduced renal clearance leads to accumulation of ezetimibe-glucuronide in plasma, increasing the risk of hepatotoxicity — ezetimibe should be discontinued in all renal transplant patients receiving cyclosporine
D) Cyclosporine has no clinically meaningful pharmacokinetic interaction with ezetimibe because ezetimibe is eliminated entirely via biliary-fecal excretion without undergoing any systemic metabolism; cyclosporine's CYP450 and transporter inhibitory effects are irrelevant to ezetimibe's pharmacokinetic profile, and no dose adjustment is needed
E) Cyclosporine inhibits OATP1B1 (organic anion transporting polypeptide 1B1) and MRP2 (multidrug resistance-associated protein 2) hepatic transporters, impairing biliary excretion of ezetimibe-glucuronide and reducing its enterohepatic recirculation; this interaction increases plasma exposure of ezetimibe and its glucuronide by approximately 3.4-fold — the combination should be used with caution, the dose of ezetimibe should not exceed 10 mg, and the clinical benefit-risk should be assessed given the already-approved 10 mg ceiling dose

ANSWER: E

Rationale:

Ezetimibe undergoes glucuronide conjugation in the intestinal wall and liver, producing ezetimibe-glucuronide, which is pharmacologically active and undergoes enterohepatic recirculation via biliary excretion and reabsorption. This biliary excretion step is mediated by hepatic efflux transporters including MRP2 (ABCC2), and hepatic uptake involves OATP transporters. Cyclosporine is a broad-spectrum inhibitor of multiple hepatic transporters including OATP1B1 (SLCO1B1) and MRP2, as well as intestinal P-glycoprotein. Clinical pharmacokinetic studies have demonstrated that co-administration of cyclosporine with ezetimibe increases the AUC (area under the plasma concentration-time curve) of ezetimibe and ezetimibe-glucuronide by approximately 3.4-fold. This increase in systemic exposure is driven primarily by impaired biliary excretion and reduced enterohepatic recirculation, not by CYP450-mediated metabolism changes — consistent with ezetimibe's CYP-independent glucuronidation pathway. The prescribing information for ezetimibe states that the combination should be used with caution in patients receiving cyclosporine, that ezetimibe doses should not exceed 10 mg daily (the standard approved dose), and that the incremental cardiovascular benefit of ezetimibe versus the potential risks of increased systemic exposure should be weighed given the transplant context. This interaction is clinically distinct from the statin-cyclosporine interaction, which involves CYP3A4 inhibition and carries a much higher risk of myopathy. Option A: Ezetimibe is not metabolized by CYP3A4. Its primary metabolic pathway is glucuronidation via UGT enzymes, which are not inhibited by cyclosporine. The premise of CYP3A4-mediated first-pass metabolism of ezetimibe is pharmacokinetically incorrect. There is also no approved 5 mg formulation of ezetimibe. Option B: Cyclosporine does not induce intestinal P-gp in a clinically meaningful way that would reduce ezetimibe efficacy. The clinical pharmacokinetic data show increased ezetimibe exposure with cyclosporine co-administration — not decreased exposure. The direction of the interaction described in this option is opposite to the established pharmacokinetic finding. Option C: Ezetimibe-glucuronide is eliminated primarily via biliary-fecal excretion, not renal tubular secretion. Renal excretion is a minor elimination pathway for ezetimibe and its metabolite. The characterization of the interaction as driven by renal tubular secretion impairment is pharmacokinetically incorrect, and blanket discontinuation in all renal transplant patients is not guideline-supported. Option D: While ezetimibe's primary elimination is indeed biliary-fecal and it is not metabolized by CYP450 enzymes, it is incorrect to conclude that cyclosporine has no pharmacokinetic interaction with ezetimibe. The well-documented transporter-mediated interaction via OATP1B1 and MRP2 inhibition produces a clinically significant approximately 3.4-fold increase in ezetimibe and ezetimibe-glucuronide exposure that requires clinical attention.

11. A 45-year-old man with heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing has an LDL-C of 186 mg/dL on high-intensity rosuvastatin 40 mg daily. He has no established ASCVD. His 10-year cardiovascular risk is estimated at 18%. Which of the following best describes the appropriate next step in LDL-C lowering therapy and the pharmacological rationale for the chosen sequence?

A) The patient should be switched from rosuvastatin to pitavastatin 4 mg daily, as pitavastatin has a unique dual mechanism of HMG-CoA reductase inhibition combined with direct NPC1L1 blockade; this makes it superior to rosuvastatin as monotherapy in HeFH patients and eliminates the need for add-on therapy in most cases
B) Ezetimibe 10 mg should be added to rosuvastatin as the next step, exploiting the complementary mechanisms of intestinal absorption blockade and hepatic synthesis inhibition; if LDL-C remains above the guideline target of less than 70 mg/dL (or less than 55 mg/dL per some HeFH guidelines) after ezetimibe addition, a PCSK9 inhibitor represents the appropriate third agent — following the stepwise intensification sequence supported by ACC/AHA guidelines for HeFH management
C) A PCSK9 inhibitor should be added immediately without first trying ezetimibe, because HeFH patients with LDL-C above 160 mg/dL on maximum statin therapy have a documented failure of ezetimibe to achieve any meaningful additional LDL-C reduction due to constitutive upregulation of hepatic cholesterol synthesis that overwhelms intestinal absorption blockade
D) LDL apheresis should be initiated immediately because HeFH patients with LDL-C above 150 mg/dL on statin monotherapy are defined as refractory to pharmacological therapy; all drug additions are futile once this threshold is crossed, and apheresis is the only intervention with evidence for cardiovascular event reduction in this LDL-C range
E) Niacin 1.5 g daily should be added to rosuvastatin as the preferred second agent in HeFH because niacin specifically reduces hepatic VLDL secretion, addressing the overproduction of LDL precursor particles that is the primary driver of LDL-C elevation in HeFH; ezetimibe and PCSK9 inhibitors do not address this overproduction mechanism

ANSWER: B

Rationale:

In heterozygous familial hypercholesterolemia, the underlying defect — reduced LDL receptor function due to LDLR mutation — means that hepatic LDL-C clearance is impaired from birth, resulting in lifelong LDL-C elevation that statins alone frequently cannot reduce to guideline targets despite maximally tolerated doses. Current ACC/AHA guidelines and the European Atherosclerosis Society HeFH consensus recommend a stepwise intensification approach: high-intensity statin as first-line, ezetimibe addition as the logical second step (exploiting the complementary mechanism of intestinal absorption blockade on top of hepatic synthesis inhibition, typically providing an additional 15–20% LDL-C reduction), and PCSK9 inhibitor addition as the third step if LDL-C targets remain unmet. For HeFH patients with established ASCVD or very high risk, the LDL-C target is less than 55 mg/dL per European guidelines or less than 70 mg/dL per ACC/AHA with consideration of less than 55 mg/dL in very high-risk individuals. For this patient without established ASCVD at 18% 10-year risk, less than 70 mg/dL is a reasonable target. His LDL-C of 186 mg/dL on maximum rosuvastatin requires at minimum one additional agent, and ezetimibe — inexpensive, oral, well-tolerated, and mechanistically rational — is the appropriate next step before escalating to injectable PCSK9 inhibitor therapy. Option A: Pitavastatin does not have dual HMG-CoA reductase inhibition plus direct NPC1L1 blocking activity. Pitavastatin is a statin with the same mechanism as rosuvastatin — HMG-CoA reductase inhibition — and no intestinal cholesterol absorption activity. Switching from one high-intensity statin to another of lower intensity is not appropriate management for a patient whose LDL-C remains markedly above target. Option C: Ezetimibe does provide meaningful additional LDL-C reduction in HeFH patients on maximum statin therapy — typically 15–20% further reduction. The premise that constitutive hepatic cholesterol synthesis upregulation in HeFH renders ezetimibe ineffective is not supported by clinical evidence. Guidelines support ezetimibe addition before PCSK9 inhibitor escalation precisely because it provides clinically significant incremental LDL-C lowering at substantially lower cost and with oral administration. Option D: LDL apheresis is not indicated at an LDL-C threshold of 150 mg/dL on statin monotherapy. Apheresis is generally reserved for HeFH or HoFH patients with LDL-C above 200 mg/dL (or above 160 mg/dL with established ASCVD) who have failed maximum tolerated pharmacological therapy including PCSK9 inhibitors. Declaring pharmacological therapy futile at this stage is premature and not consistent with current guidelines. Option E: Niacin is not a guideline-recommended second agent in HeFH management. The AIM-HIGH and HPS2-THRIVE trials demonstrated that adding niacin to statin therapy produced no incremental cardiovascular event reduction despite raising HDL-C and reducing triglycerides. Niacin is no longer considered a preferred add-on agent for LDL-C lowering in contemporary cardiovascular guidelines, and it does not specifically target the LDL receptor deficiency that underlies HeFH.

12. A 58-year-old woman with established ASCVD and an LDL-C of 74 mg/dL on rosuvastatin 20 mg plus ezetimibe 10 mg is being considered for evolocumab. Her cardiologist discusses the dosing options. Which of the following correctly describes evolocumab's approved dosing schedules and identifies the pharmacokinetic rationale for why both schedules achieve equivalent LDL-C lowering despite different dosing intervals?

A) Evolocumab is approved only as a monthly 420 mg subcutaneous injection; there is no every-2-week dosing option for evolocumab — that schedule applies only to alirocumab, which was approved at a lower antibody concentration requiring more frequent administration to maintain therapeutic PCSK9 neutralization throughout the dosing interval
B) Evolocumab is approved at 140 mg every 2 weeks or 420 mg monthly, but the monthly dose produces 30% greater LDL-C reduction than the every-2-week schedule because the higher peak concentration drives a larger initial receptor protection effect that persists throughout the monthly interval despite trough PCSK9 concentrations returning to near-baseline levels between doses
C) Evolocumab is approved at 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly; both regimens achieve equivalent mean LDL-C reduction of approximately 60% because the total monthly antibody exposure (AUC) is equivalent between regimens, maintaining PCSK9 neutralization at levels sufficient to protect LDL receptors from degradation throughout the dosing interval despite different peak-trough profiles
D) Evolocumab is approved only for every-2-week dosing at 140 mg subcutaneously; the 420 mg monthly regimen was studied in clinical trials but not approved because PCSK9 concentrations rebound to above-baseline levels in the third and fourth weeks after a monthly injection, paradoxically increasing LDL receptor degradation and transiently raising LDL-C above pre-treatment values
E) Evolocumab's two approved dosing schedules differ in their mechanism of LDL receptor protection — the 140 mg every-2-week schedule maintains continuous PCSK9 neutralization and acts via receptor recycling protection, while the 420 mg monthly schedule reaches concentrations sufficient to irreversibly inactivate PCSK9 via covalent binding, providing longer protection that allows the monthly interval

ANSWER: C

Rationale:

Evolocumab (Repatha) is FDA-approved in two dosing regimens for LDL-C lowering in adults: 140 mg subcutaneously every 2 weeks, or 420 mg subcutaneously once monthly (administered as three consecutive 140 mg injections). Both regimens produce equivalent mean LDL-C reduction of approximately 60% from baseline, as established in the PROFICIO clinical development program and confirmed in the FOURIER outcomes trial, which allowed either regimen at investigator discretion. The pharmacokinetic basis for equivalent efficacy despite different intervals relates to total monthly antibody exposure — the AUC (area under the concentration-time curve) over a monthly period is equivalent between the two regimens (3 × 140 mg = 420 mg per month in both cases). PCSK9 is a secreted protein with ongoing hepatic production; evolocumab neutralizes circulating PCSK9 throughout the dosing interval, and at both regimens, sufficient antibody concentrations are maintained to provide meaningful LDL receptor protection across the full interval. The choice between regimens is primarily driven by patient preference and adherence considerations — some patients prefer less frequent monthly administration; others prefer the lower individual injection volume of the every-2-week regimen. Option A: Evolocumab is approved in both the every-2-week 140 mg and monthly 420 mg regimens. It is incorrect that only monthly dosing is approved for evolocumab. Alirocumab is also approved at every-2-week dosing (75 mg or 150 mg), but the description of only one regimen for evolocumab is factually incorrect. Option B: The monthly 420 mg and every-2-week 140 mg regimens produce equivalent, not different, LDL-C reductions. Clinical trial data from the PROFICIO program demonstrated no clinically significant difference in LDL-C lowering between the two dosing schedules. The premise that the monthly dose produces 30% greater LDL-C reduction is not supported by trial evidence. Option D: The 420 mg monthly regimen is fully FDA-approved — it is not a trial-only regimen that was rejected from approval. PCSK9 concentrations do show some rebound toward the end of the monthly dosing interval, but LDL-C lowering remains equivalent to the every-2-week schedule and there is no clinically meaningful transient increase in LDL-C above pre-treatment values documented in the clinical program. Option E: Evolocumab does not act by covalent binding to PCSK9 at either dose. Both dosing schedules involve the same mechanism — reversible non-covalent monoclonal antibody binding to the catalytic domain of circulating PCSK9 protein. There is no irreversible covalent inactivation mechanism associated with the 420 mg monthly dose.

13. A 19-year-old woman with homozygous familial hypercholesterolemia (HoFH) due to two receptor-negative LDLR mutations has an LDL-C of 680 mg/dL despite maximum-dose rosuvastatin plus ezetimibe. Her cardiologist is choosing between adding evolocumab versus lomitapide. Which of the following correctly explains why evolocumab is expected to produce minimal LDL-C lowering in this patient while lomitapide remains an appropriate option?

A) Evolocumab's mechanism depends entirely on the presence of functional LDL receptors that can recycle to the hepatocyte surface once freed from PCSK9-mediated degradation; in receptor-negative HoFH, no functional LDLR exists to recycle — evolocumab therefore has no receptor pool to protect, and PCSK9 inhibition produces no meaningful increase in LDL-C clearance; lomitapide, by contrast, inhibits microsomal triglyceride transfer protein (MTP) inside hepatocytes and enterocytes, blocking VLDL and chylomicron assembly upstream of LDL receptor-mediated clearance and reducing LDL-C by a receptor-independent mechanism
B) Evolocumab cannot be used in HoFH because the FDA label explicitly contraindicates PCSK9 inhibitors in patients with two null LDLR alleles; lomitapide carries no such contraindication and is the only pharmacological agent approved specifically for HoFH without restriction based on mutation type
C) Lomitapide is preferred over evolocumab in HoFH because it directly inhibits PCSK9 secretion from hepatocytes via an intracellular mechanism distinct from extracellular antibody neutralization, producing greater PCSK9 suppression than evolocumab and thereby protecting whatever residual LDL receptor function remains even in receptor-negative HoFH patients
D) Evolocumab produces minimal LDL-C lowering in HoFH because its molecular weight prevents it from reaching hepatocyte surfaces in sufficient concentrations in patients with severely dysfunctional lipid metabolism; lomitapide's smaller molecular weight and oral bioavailability allow it to achieve therapeutic hepatocyte concentrations that evolocumab cannot
E) Both evolocumab and lomitapide are equally effective in receptor-negative HoFH; the choice between them is determined exclusively by tolerability — evolocumab causes injection-site reactions while lomitapide causes severe myopathy — and the cardiologist should select based on the patient's prior drug reaction history rather than on mechanistic grounds

ANSWER: A

Rationale:

The distinction between receptor-negative and receptor-defective HoFH is the central pharmacological determinant of PCSK9 inhibitor response in homozygous familial hypercholesterolemia. In receptor-defective HoFH, patients retain 1–25% of normal LDL receptor activity; evolocumab, by preventing PCSK9-mediated degradation of these residual receptors, allows them to recycle more efficiently and can produce clinically meaningful LDL-C reductions of 20–30% or more. In receptor-negative HoFH — both alleles carrying null mutations producing no functional LDLR protein — there are no LDL receptors to protect from PCSK9 degradation. Evolocumab's entire mechanism depends on preserving receptor recycling; if no receptors exist, there is nothing to preserve, and the drug produces minimal or no LDL-C lowering. This mutation-dependent response was documented in the TESLA trial of evolocumab in HoFH. Lomitapide operates through a completely different and receptor-independent mechanism: it inhibits MTP (microsomal triglyceride transfer protein) inside the endoplasmic reticulum of hepatocytes and enterocytes, blocking the lipidation of apolipoprotein B-100 (apoB-100) required for VLDL assembly and the lipidation of apoB-48 required for chylomicron assembly. By preventing VLDL secretion from the liver, lomitapide reduces the hepatic output of LDL precursor particles — an upstream intervention that does not require any LDL receptor function and therefore works in receptor-negative HoFH patients. Lomitapide is FDA-approved as an adjunct to a low-fat diet and other lipid-lowering treatments in adults with HoFH, and its LDL-C lowering of approximately 40–50% from baseline is independent of LDLR mutation type. Option B: Evolocumab does not carry an FDA label contraindication in patients with two null LDLR alleles. The prescribing information notes reduced efficacy in receptor-negative HoFH patients — it does not prohibit use. The clinical decision to use or not use evolocumab in this population is based on expected efficacy given mutation type, not a regulatory contraindication. Option C: Lomitapide does not inhibit PCSK9 secretion and has no mechanism related to PCSK9 biology. Lomitapide is an MTP inhibitor that acts inside the hepatocyte endoplasmic reticulum on VLDL assembly, entirely upstream of and unrelated to the PCSK9-LDL receptor axis. Describing lomitapide as a PCSK9 inhibitor is a fundamental mechanistic error. Option D: Evolocumab's minimal efficacy in receptor-negative HoFH is not caused by pharmacokinetic failure to reach hepatocyte surfaces. Evolocumab achieves adequate plasma concentrations and fully neutralizes circulating PCSK9 even in HoFH patients — the problem is that PCSK9 neutralization produces no downstream LDL-C benefit when no LDL receptors exist to be protected. The mechanism failure is pharmacodynamic, not pharmacokinetic. Option E: Evolocumab and lomitapide are not equally effective in receptor-negative HoFH. Evolocumab produces minimal LDL-C lowering in receptor-negative patients while lomitapide produces approximately 40–50% LDL-C reduction regardless of receptor type. The choice between them is mechanistically determined — not merely a tolerability preference. Lomitapide's primary adverse effects are hepatic (elevated transaminases, hepatic steatosis) and gastrointestinal, not myopathy.